CatalystTech/AI
OpenAI acquires Orchestra Bio in AI push for new drugs
OpenAI acquiring Orchestra Bio signals AI expansion into drug development.
Context
What happened: OpenAI said on Tuesday it acquired platform startup Orchestra Bio to increase the use of artificial intelligence in providing new drug treatments. Terms of the deal were not disclosed.
Why it matters: OpenAI said it will combine its Rosalind with Orchestra Bio as part of the acquisition, per the content provided.
What changed
OpenAI said on Tuesday it acquired platform startup Orchestra Bio to increase the use of artificial intelligence in providing new drug treatments. Terms of the deal were not disclosed.
Why it matters
OpenAI said it will combine its Rosalind with Orchestra Bio as part of the acquisition, per the content provided.
← Dashboard
Oct 20, 2026 06:37 PM ET